GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Tax Expense

Qualis Innovations (Qualis Innovations) Tax Expense : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations Tax Expense?

Qualis Innovations's tax expense for the months ended in Mar. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Qualis Innovations Tax Expense Historical Data

The historical data trend for Qualis Innovations's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations Tax Expense Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only - 0.28 - - -

Qualis Innovations Quarterly Data
Oct10 Jan11 Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Qualis Innovations Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualis Innovations  (OTCPK:QLIS) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Qualis Innovations Tax Expense Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualis Innovations (Qualis Innovations) Business Description

Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751